1 :s 1 A :: investors ana Me<lta, ---
`
`Yage 1 ot 1
`
`Q - - - - ----INVESTORS AND MEDIA - - - - - - - - -
`
`News Release
`
`<<Back
`ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-
`. 200 i-
`dally)
`IRVINE, Calif., Dec. 20 /PRNewswire-Firstcall/ -- ISTA Pharmaceuticals, Inc.
`(Nasdaq: ISTA), announced today the Company has submitted a New Drug
`Application (NDA) to the U.S. Food and Drug Administration (FDA) for Xibrom(TM)
`QD (once-daily). The Company is seeking approval for Xibrom QD as a treatment
`for inflammation, pain, and photophobia following cataract surgery.
`
`Xibrom(TM) (bromfenac ophthalmic solution)
`
`Xibrom Is a topical non-steroidal anti- inflammatory compound for the treatment of
`ocular inflammation and pain. Xlbrom, approved In 2005, Is the first and only FDA(cid:173)
`approved twice-dally NSAID tor Inflammation and reduction of pain following
`cataract surgery. Xlbrom is the fastest growing ophthalmic product in 2007,
`according to IMS data. Xibrom, under a
`·
`nt trade name but identical
`I
`formulation was launched in Japan in 2000 b Sen ·u P armaceutlcals
`acquire
`.S. mar e ing ngh
`for
`rom in 2002 an
`launched the produg_ iJl J~
`'u.s. in 2005.
`
`ABOUT ISTA PHARMACEUTICALS
`
`ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products
`and product candidates addressing the $3.2 billion U.S. prescription ophthalmic
`industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry
`eye. The Company currently markets three products and is developing a strong
`product pipeline to fuel future growth and market share. The Company's product
`development and commercialization strategy Is to launch a new product every 12 to
`18 months, thereby continuing its growth to become the leading niche ophthalmic
`pharmaceutical company In the U.S. For additional information regarding ISTA,
`please visit ISTA Pharmaceuticals' website at http://www.lstavlsion.com.
`
`SOURCE ISTA Pharmaceuticals, Inc.
`
`CONTACT: Vince Anido, +1-949-788-5311, vanido@istavision.com, or
`Investors, Lauren Silvernail, + 1-949-788-5302, lsilvemail@istavislon.com,
`both of ISTA Pharmaceuticals; Media, Justin Jackson, jjackson@burnsmc.com, or
`Investors, Jullane Snowden, +1-212-213-0006, jsnowden@burnsmc.com, both of
`Burns McClellan, for ISTA Pharmaceuticals
`
`http://phx.corporate-ir.net/phoenix.zhtmJ?c= 121179&p=irol-newsArticle _pf&ID= 1 089494... 3/1912008
`
`Metrics EX1034, Page 1